If you have read a drug label and wondered what is immunogenicity, the plain meaning is simple. Immunogenicity is a medicine's capacity to trigger an immune response against itself or related proteins, or to cause immune-related clinical events.

Labs usually measure this response through anti-drug antibodies (ADAs), which are immune proteins that bind to a medicine. A subset called neutralizing antibodies blocks the medicine's biological activity. By contrast, hypersensitivity is an adverse physical reaction, such as an allergic rash, swelling (angioedema), or anaphylaxis.

A positive antibody lab test is not an allergy diagnosis. Many people who test positive for antibodies have no allergy symptoms at all.

What is immunogenicity in official FDA terms?

FDA's August 2014 final guidance, Immunogenicity Assessment for Therapeutic Protein Products, sets the formal standard. It defines the term as "the propensity of the therapeutic protein product to generate immune responses to itself and to related proteins". That definition also includes the potential "to induce immunologically related adverse clinical events".

The guidance adds that "the scientific principles may also apply to related products and biological entities, for example, peptides". Neutralizing antibodies block biological activity. Non-neutralizing antibodies bind without directly blocking that activity, but can still change how the body clears a medicine or affect safety.

Of non-neutralizing antibodies, the 2014 guidance notes, "However, they may have no apparent effect on either safety or efficacy". Responses depend on the product and the patient.

Sequence, clumped molecules (aggregates), impurities, formulation, route, exposure length, and patient immune traits all matter. Resembling a human protein does not guarantee zero immune response.

A May 2021 historical FDA guidance on synthetic peptide generics addressed manufacturing by-products. It noted that "peptide-related impurities may create the potential for differences in immunogenicity" or affect safety and effectiveness. It asked generic makers to check new impurities for "sequences that have an increased affinity for major histocompatibility complex (MHC), known as T-cell epitopes".

As of October 17, 2026, the day this article was written, that May 2021 document is historical context. On July 28, 2026, FDA announced 17 revised draft product-specific guidances for peptide generics and withdrew the 2021 guidance. FDA withdrew it because "it no longer reflects FDA’s current scientific thinking", a shift covered in our guide to bioequivalence.

FDA's July 2026 revised draft guidance on generic tirzepatide is marked "Draft – Not for Implementation". It says innate immune evaluation "can be accomplished through analyzing aggregates and non-active ingredient-related impurities, which may alter the product’s immunogenicity profile". When impurities and aggregates match the reference drug within set limits, "in vitro innate immune testing may not be scientifically necessary".

How GLP-1 antibodies appear on Zepbound and Wegovy labels

In the Zepbound prescribing information ("Revised: 8/2026"), Section 12.6 reports anti-tirzepatide antibodies in "64.5% (1591/2467)" of weight-study patients. That is nearly 2 in 3 treated adults across weight-reduction studies 1 and 2.

Neutralizing antibodies against GIP-receptor and GLP-1-receptor activity appeared in 2.8% and 2.7% of treated patients, or under 3 in 100 people. In Section 6.1, hypersensitivity reactions (mostly skin reactions) occurred in "6.2%" of antibody-positive patients versus "3%" without antibodies.

In type 2 diabetes, a 2024 analysis in the Journal of Clinical Endocrinology & Metabolism pooled 5,025 tirzepatide-treated adults across seven SURPASS trials. Over 40 to 52 weeks, "TE ADA developed in 51.1% of tirzepatide-treated patients" (treatment-emergent antibodies, or about half of patients).

The comparison of antibody-positive and antibody-negative patients was not randomized. The analysis found no antibody effect on drug handling or glycemic efficacy. In those trials, "The majority of hypersensitivity and injection site reactions were nonserious and nonsevere".

Those trial figures come from the manufactured brand product. Tirzepatide and semaglutide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy. Each is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

The Wegovy prescribing information ("Revised: 6/2026") covers immunogenicity in Section 12.6 and postmarketing reports in Section 6.2. At the 2.4 mg injection dose, "50/1709 (3%)" of adults in 68-week Studies 2 and 3 developed antibodies. In 72-week Studies 8 and 9 using a new assay at that dose, "34/304 (11.2%)" tested positive, or about 1 in 9 people.

Label detail Zepbound (Revised: 8/2026) Wegovy (Revised: 6/2026)
Weight-study ADA rate (§12.6) 64.5% (1591/2467) in Studies 1–2 50/1709 (3%) in Studies 2–3; 34/304 (11.2%) with new assay in Studies 8–9
Effect on disposition or efficacy No clinically significant effect identified No clinically significant effect on injection blood levels identified; evidence insufficient for biological activity, safety, or effectiveness

Both labels warn that "Differences in assay methods preclude meaningful comparisons" across studies. These percentages cannot rank semaglutide against tirzepatide, and neither label proves antibodies are always harmless.

Both labels contraindicate their product in patients with a prior serious reaction to that drug or one of its ingredients. Zepbound Section 5.6 directs patients with hypersensitivity reactions to "promptly seek medical attention and discontinue use of ZEPBOUND". Wegovy Section 5.7 says to "discontinue use of WEGOVY, treat promptly per standard of care" and monitor until symptoms resolve.

Why FDA raises peptide immunogenicity for compounded drugs

Two manufacturing issues often drive peptide immunogenicity discussions: aggregates (clumped molecules) and peptide-related impurities (altered sequences or breakdown products). A 2023 review abstract in Drug Discovery Today explains why trace synthesis by-products matter. It notes that "impurities can have potential to elicit unwanted immune responses owing to the introduction of T-cell epitopes".

A December 2025 laboratory study in Frontiers in Immunology examined generic teriparatide products. Researchers screened 34 observed peptide impurities by computer and tested seven observed plus two theoretical impurities.

Using HLA-binding and human donor-cell tests, "The orthogonal approaches identified multiple impurities as more immunogenic than TPT". Those laboratory tests measure relative cell responses, not clinical allergy rates or compounded BPC-157 risk.

On FDA's compounding safety risks page (current as of April 22, 2026), BPC-157 is not in the active FDA Category 2 table. Instead, it sits in the table of substances whose nominations "were withdrawn by the nominators".

There, FDA states that compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration". The entry also notes "complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization". According to the page, "FDA has identified no, or only limited, safety-related information for the proposed routes of administration".

In July 23, 2026 FDA advisory committee slides, staff reiterated that "BPC-157 may pose a significant risk for immunogenicity". The slides noted this risk is "potentially amplified by aggregation as well as potential peptide-related impurities".

BPC-157 is not FDA-approved, and neither its evaluated free-base nor acetate form is part of an approved drug. Regulatory status is context rather than a measured reaction rate. For a compounded peptide, a licensed provider may still prescribe — that decision is between you and your doctor.

Three mistakes people make with immunogenicity

First is equating antibodies with allergy. An antibody test is a laboratory finding, not a symptom check. Urgent symptoms like hives or swelling require prompt medical care, as covered in our guide to peptide allergic reactions.

Second is assuming a human-like sequence cannot trigger a response. Resembling a human protein does not guarantee zero immune response when aggregates, impurities, or injection routes are involved.

Third is assuming a Certificate of Analysis rules out immune responses. A Certificate of Analysis documents only the batch tests actually reported, not how your immune system will react.

On its page Understanding the Risks of Compounded Drugs, FDA writes that "Compounded drugs are not FDA-approved". The agency "does not review their safety, effectiveness or quality before they are marketed".

FDA also notes that compounded medicines "can serve an important medical need for patients". Neither brand-label antibody rates nor raw-ingredient test reports establish an immunogenicity rate for compounded semaglutide or tirzepatide.

How providers approach immunogenicity in practice

The sources discussed here do not establish an antibody rate for compounded BPC-157, semaglutide, or tirzepatide. They also do not establish a routine antibody-testing protocol for those preparations.

For a prescription, exact formulation details and your reaction history matter, and a licensed U.S. compounding pharmacy dispenses the medicine. At Promise, a licensed provider reviews every request and not everyone qualifies.